Modality
Gene Therapy
MOA
SGLT2i
Target
B7-H3
Pathway
PD-1/PD-L1
NMOSD
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
~Jan 2020
→ ~Apr 2021
Phase 2
~Jul 2021
→ ~Oct 2022
Phase 3
~Jan 2023
→ ~Apr 2024
NDA/BLA
Jul 2024
→ Dec 2029
NDA/BLACurrent
NCT08325398
1,605 pts·NMOSD
2024-07→2029-12·Terminated
1,605 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-12-053.7y awayPh3 Readout· NMOSD
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2029-12-05 · 3.7y away
NMOSD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08325398 | NDA/BLA | NMOSD | Terminated | 1605 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| BAY-3308 | Bayer | Phase 1 | ALK |